Career developmental program (CDP) is a particulariy important activity for translational research programs. By its very nature, translational research is multidisciplinary. Because ofthe depth of knowledge required of each individual discipline, our present edicational structure seldom allows trainees to function in a multidisciplinary environment. This Career Developmental Program is designed to provide the incentive and structure necessary to bring junior investigators into multidisciplinary translational research arena. A key to success of this endeavor is the availabililty and willingness of mentors throughout the SARC institutions to meet the challenges of translational research. This Program will be chaired by Dr. Richard Goriick, Director, Sarcoma Research Laboratory, Albert Einstein College of Medicine , Division Chief, Pediatric Hematology/Oncology, The Children's Hospital at Montefiore and Vice Chairman, Department of Pediatrics, The Children's Hospital at Montefiore and will be supported by the program Administrative Director, Denise Reinke, MS, NP, Chief Operating Officer of SARC. They are joined by a committee including leaders in the fields of medical oncology (Dr. Schuetze), pediatric oncology (Dr. Mackall), tumor biology (Dr. Lev), drug resistance (Dr. Hornicek), cancer genetics (Drs. Fletcher and van de Rijn), cancer statistics (Dr. Crowley), imaging biomarkers (Dr. Schwartz) and patient advocacy (Dr. Thorton). These outstanding senior mentors, representing Albert Einstein College of Medicine, Brigham and Women's Hospital, Cancer Research and Biostatistics (CRAB), Columbia University, Massachusetts General Hospital, MD Anderson, National Cancer Institute Intramural Program, Sarcoma Foundation Of America, Stanford University School ofMedicine, University of Michigan , have enthusiastically agreed to steward the SARC Sarcoma SPORE Career Developmental Program, with responsibility for selection and support of the SPORE career development awardees.

Public Health Relevance

Providing research support and protected time for junior investigators is a general priority in translational cancer research, and particulariy so in sarcoma research, where the funding mechanisms are typically fewer than for other cancer disease types. SPORE support will improve the likelihood that each awardee will prceed to independent investigator status, and - in turn - these talented individuals will add dimension to the SARC Sarcoma SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA168512-01
Application #
8395612
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2012-09-26
Project End
2017-08-31
Budget Start
2012-09-26
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$173,063
Indirect Cost
$9,998
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92
Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23
Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13
Mariño-Enríquez, Adrián; Bovée, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73
Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358
Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4
Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415
De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28

Showing the most recent 10 out of 86 publications